How can we intervene with MRD-directed therapy within and outside of transplantation?

During a meeting of the AML Hub Steering Committee, held on May 8, 2024, Jeffrey Lancet chaired a discussion on the question: How can we intervene with measurable residual disease (MRD)-directed therapy within and outside of transplantation? This featured contributions from Charles Craddock, Gail Roboz, and Yasushi Miyazaki. 

Lancet discusses the use of MRD-directed therapy, particularly in patients with MRD-positive disease, and the strategies for those transitioning from MRD positivity to negativity. The discussion includes insights from the QUAZAR study and raises concerns about the reliability of measuring MRD conversion, especially with flow cytometry. Risk stratification at diagnosis was also addressed, focusing on countries where MRD assessment for AML is not well established. The steering committee members recognize the unmet need to establish MRD as a definitive endpoint in clinical trials and to research the optimal timing for post-transplant MRD assessment.